"Astrocytes!" Something new to me. Gives a whole new meaning to the concept of "Inner space"... Nic 57/15 On Thu, Apr 30, 2009 at 8:27 PM, mschild <[log in to unmask]> wrote: > ScienceDaily (Apr. 30, 2009) — Scientists have identified a protein that > appears not only to be central to the process that causes Parkinson's > disease > but could also play a role in muting the high from methamphetamine and > other > addictive drugs. > The action of the protein, known as organic cation transporter 3 or oct3, > fills a longstanding gap in scientists' understanding of the brain damage > that > causes symptoms like tremor, stiffness, slowness of movement and postural > instability. While these are found mainly in patients with Parkinson's > disease, there are more than three dozen other known causes of this array > of > symptoms, known as "parkinsonism." > In a paper published online this week in the Proceedings of the National > Academy of Sciences, scientists at the University of Rochester Medical > Center > and Columbia University have shown that oct3, a protein that shepherds > molecules into and out of cells, plays a critical role, bringing toxic > chemicals to the doorstep of the brain cells that die in patients with > Parkinson's disease. The team found that oct3 is involved in the brain's > response to addictive drugs like methamphetamine as well. > Precisely what causes Parkinson's disease remains largely a mystery. Some > cases have a known genetic basis, and most others are attributed to > environmental causes or a combination of gene-environment interactions. > Doctors know that symptoms of Parkinson's stem from the death of a very > small, > specialized group of brain cells known as dopamine neurons, which produce a > chemical needed by another area of the brain to help us move freely. It's > not > until most of those brain cells have already died that patients begin to > show > symptoms. > For decades, scientists have been trying to understand why those cells die. > The latest paper supports a role for astrocytes, a type of cell that is the > most common in the brain but which has been often overlooked by scientists > focused more on cells known as neurons that send electrical signals. > Astrocytes' role in Parkinson's is no surprise to brain experts who have > also > identified them as a player in Alzheimer's disease, amyotrophic lateral > sclerosis, epilepsy, and other diseases. > "Astrocytes are definitely much more than support cells in the brain," said > Kim Tieu, Ph.D., a corresponding author of the paper and assistant > professor > in the Department of Environmental Medicine at the University of Rochester > Medical Center. "Scientists are discovering their involvement in many > diseases. The latest results point to their role in Parkinson's disease." > Tieu initiated the study while a post-doctoral research associate in the > laboratory of Serge Przedborski, M.D., Ph.D., the Page and William Black > Professor of Neurology at Columbia University and a corresponding author. > They > chose to study how the brain handles a chemical known as MPTP, which > ultimately damages the exact same brain cells that are injured in patients > with Parkinson's disease. While MPTP does not cause Parkinson's disease, > scientists regularly use it as a model for the disease because it causes an > identical type of brain damage. > In the brain, MPTP is converted primarily in astrocytes to a chemical > called > MPP+, which is deadly to dopamine neurons. More than 20 years ago, as a > graduate student with Solomon Snyder, M.D., Jonathan Javitch, M.D., Ph.D., > now > professor of psychiatry and pharmacology at Columbia and an author on the > current paper, concluded that MPP+ is released from astrocytes before it > kills > dopaminergic neurons. But exactly how MPP+ is freed from astrocytes was > unknown. > In this week's PNAS paper, the scientists finger oct3 as the shepherd that > escorts toxic MPP+ out of the astrocytes and into the space surrounding > dopamine neurons. That's where another molecule known as the dopamine > transporter picks it up and brings it into the neuron itself. > When the team blocked or genetically removed oct3 in mice, the dopamine > neurons in the brains did not die despite the presence of MPTP in the > brain. > Without oct3, MPP+ remained sequestered inside astrocytes and did not > affect > the dopamine neurons. And when oct3 was present in the usual amounts, > dopamine > neurons died as expected. > "The neurons affected in Parkinson's disease don't live in isolation in the > brain," said Przedborski. "You must understand the brain environment as a > whole to understand disease. For many years, people had a neuron-centric > view > of neurodegenerative diseases. But more and more scientists are realizing > that > if you wish to understand the process of neurodegeneration, you must take > into > account the astrocytes, the microglia, as well as the neurons. Astrocytes > maintain an intimate relationship with neurons, and to understand one, you > have to understand the other." > The team also analyzed brain tissue from people who died of Parkinson's > disease and found that oct3 is active in astrocytes in the brain region > affected by Parkinson's disease. They found the same thing in mice, where > the > absence of oct3 correlated exactly to areas of the brain where neurons were > not damaged. > The team also showed that oct3 plays a role in the brain's response to > methamphetamine. Oct3 is critical for helping astrocytes soak up excess > dopamine in the space around neurons. When dopamine isn't removed as > quickly > or thoroughly as usual, people can feel euphoric, but they can also > experience > brain damage. The finding that oct3 may play a role matches other > scientists' > observations that people in whom oct3 activity is reduced have a higher > potential for addiction. > The molecule might also offer a new target for treating depression. Many > anti- > depressants work by allowing the brain chemical serotonin to stay available > in > the brain longer than it otherwise would. Since one of oct3's functions is > to > remove serotonin from the brain, blocking it may offer a new avenue to > treat > depression. > The chemicals that the team used to block oct3 in mice would be toxic in > people, and there is no drug available for people now that blocks or boosts > oct3, Tieu and Przedborski said. But such a drug might be useful for > Parkinson's, drug addiction, and depression. > "How you choose to manipulate the function of oct3 depends on the source of > the toxic molecules," said Tieu, who is also a scientist in the > University's > Center for Neural Development and Disease. "You would try to lessen its > effects in a condition where it makes a toxic molecule available to > vulnerable > cells, as illustrated in the current model of Parkinson's disease. But in > the > case of drug addiction, you might try to increase it, to lessen the impact > of > a drug like methamphetamine." > Other authors at the University of Rochester include post-doctoral research > associates Mei Cui, Ph.D., Radha Aras, Ph.D., and Mamata Hatwar, Ph.D.; > graduate student Whitney Christian; medical and graduate student Phillip > Rappold; former undergraduate student Joseph Panza; and Ned Ballatori, > Ph.D., > professor of environmental medicine. At Columbia, Vernice Jackson-Lewis, > Ph.D., associate research scientist, also contributed to the research. The > work was funded by the National Institute of Environmental Health Sciences. > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto: > [log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn